This is an aggregated industry headline. Read the full story at STAT News →
STAT+: Pharmalittle: We're reading about a Novo setback, support for Replimune's melanoma drug, and more
An FDA advisory panel recommended use of an experimental Replimune treatment for advanced melanoma that the agency has rejected twice
By STAT News
· Jul 31, 2026
· via STAT News
Image: STAT News
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Reporting a new miss in one indication, Karyopharm is plowing ahead with plans to advance its XPO1 inhibitor X…
The WeekFierceBiotech ↗
Whether it's looming tariff threats or the rise of China, you need a truly global view to navigate today's bio…
The WeekBriefing
AbbVie’s Skyrizi generated $5.55 billion in second-quarter sales, nearly matching Humira’s best quarter. The r…